NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
Stallion India Sets Feb 11 as Record Date for 19:41 Rights Issue
Stallion India Fluorochemicals Limited has officially fixed February 11, 2026, as the record date for its upcoming rights issue. The company will offer 19 new equity shares for every 41 existing shares held by eligible shareholders. This corporate action is intended to raise capital from existing investors to support the company's financial objectives. Shareholders must hold the stock before the record date to be eligible for the rights entitlement.
முக்கிய அம்சங்கள்
Record date for the rights issue is fixed as Wednesday, February 11, 2026Rights entitlement ratio is set at 19 equity shares for every 41 shares heldThe issuance is being conducted under Regulation 42 of SEBI LODR RegulationsThe move aims to raise equity capital from the existing shareholder base
👀 கவனிக்க வேண்டியவை
Investors should evaluate the rights issue price once disclosed against the current market price to decide on subscription. Existing shareholders need to hold the stock by the ex-date to receive rights entitlements.
Stallion India to Expand with 10,000 MT R-32 Plant; Targets 3-4% Margin Boost
Stallion India Fluorochemicals is scaling its operations from 4 to 6 facilities, including a new 10,000 MT R-32 plant in Bhilwara and a 7,200 MTPA facility in Andhra Pradesh. The company is diversifying into specialty semiconductor gases and liquid helium with a 1,200 MTPA capacity investment. These initiatives, including backward integration, are expected to enhance profit margins by 3-4%. The company currently maintains a 10% market share in India and serves over 200 customers across 15 industries.
முக்கிய அம்சங்கள்
Received Environmental Clearance for a 10,000 MT R-32 manufacturing facility in Bhilwara, Rajasthan.Expanding footprint to 6 facilities with a new 7,200 MTPA plant in Andhra Pradesh expected by Q4 FY25-26.Investing in 1,200 MTPA liquid helium capacity to serve the high-growth semiconductor and electronics industries.Management projects that strategic backward and forward integration will improve profit margins by 3-4%.Currently holds approximately 10% market share in India's refrigerant and industrial gas sector with 200+ customers.
👀 கவனிக்க வேண்டியவை
Investors should monitor the timely commissioning of the Bhilwara and Mambattu facilities, as these are the primary catalysts for the projected margin expansion and market share growth. The entry into semiconductor gases provides a high-tech growth lever that warrants long-term attention.
Stallion India Clarifies Q3 FY26 Results; 9M PAT Surges 72.8% to ₹32.9 Crore
Stallion India Fluorochemicals issued a clarification and apology regarding inconsistent market communications for its Q3 and 9M FY26 results due to an IR-level lapse. For the nine-month period ending December 2025, the company reported a strong 41.69% revenue growth to ₹321.18 crore and a 72.81% jump in PAT to ₹32.91 crore. While Q3 EBITDA saw a slight dip of 5.21% YoY, the overall 9M performance remains robust with EBITDA growing 48.57%. The management reaffirmed its FY26 guidance of ₹430 crore revenue and ₹40 crore PAT, targeting a 30-35% CAGR over the next three years.
முக்கிய அம்சங்கள்
9M FY26 Revenue grew 41.69% YoY to ₹32,118.21 Lakhs, while PAT surged 72.81% to ₹3,290.68 Lakhs.Q3 FY26 Revenue increased 23.17% YoY to ₹10,487.90 Lakhs, though EBITDA declined 5.21% to ₹1,356.20 Lakhs.Management maintained FY26 guidance of ₹43,000 Lakhs Revenue and ₹4,000 Lakhs PAT.The company is expanding into semiconductor gases, liquid helium processing, and R-32 manufacturing.Clarification was issued to address an 'inadvertent communication lapse' at the Investor Relations level.
👀 கவனிக்க வேண்டியவை
Investors should focus on the strong 9M growth trajectory and the management's ambitious 3-year CAGR targets while monitoring for improved internal communication controls. The underlying business performance remains robust despite the reporting inconsistency.
Stallion India Receives In-Principle Approval for Rs 364 Crore Rights Issue
Stallion India Fluorochemicals Limited has secured in-principle approval from both NSE and BSE for a proposed rights issue. The company intends to raise up to Rs 364 crore through the issuance of equity shares to its existing eligible shareholders. While the specific issue price, rights ratio, and record date are yet to be finalized, this approval is a critical step in the company's capital-raising process. The final terms of the issue will be disclosed at least three working days prior to the record date.
முக்கிய அம்சங்கள்
Received in-principle approval from NSE and BSE on January 30, 2026, for the proposed rights issue.The total fundraise amount is capped at an aggregate of Rs 364 Crores.The issue involves equity shares with a face value of Rs 10 each, with the premium to be decided later.The company is required to announce the rights price and ratio at least 3 working days before the record date.The approval is subject to fulfilling standard SEBI and exchange listing conditions.
👀 கவனிக்க வேண்டியவை
Investors should monitor future announcements for the specific rights ratio and issue price to evaluate the potential dilution and the discount offered. Existing shareholders should prepare to decide whether to subscribe to the issue or renounce their rights once the record date is announced.
Stallion India Q3 & 9M FY26: 9M PAT Surges 72.8% YoY to ₹32.9 Crore
Stallion India Fluorochemicals reported robust 9M FY26 results with revenue rising 41.7% YoY to ₹321.2 crore and PAT jumping 72.8% to ₹32.9 crore. The company has already achieved approximately 82% of its full-year PAT guidance of ₹40 crore within the first nine months. Strategic expansions into semiconductor gases and the upcoming R-32 manufacturing facility are expected to boost margins by 3-4%. Management remains confident in sustaining a 30-35% CAGR over the next three years.
முக்கிய அம்சங்கள்
9M FY26 PAT surged 72.81% YoY to ₹3,290.68 Lakhs from ₹1,904.25 Lakhs.Total Revenue for 9M FY26 grew 41.69% YoY to ₹32,118.21 Lakhs.Received Environmental Clearance for a 10,000 MT R-32 facility, targeting August 2026 commissioning.Management maintains FY26 guidance of ₹430 Cr revenue and ₹40 Cr PAT, with potential to surpass it.Expanding into high-growth sectors like semiconductor gases and 1,200 MT liquid helium processing.
👀 கவனிக்க வேண்டியவை
The company is demonstrating high growth and is likely to exceed its annual guidance, making it a strong candidate for growth-oriented portfolios. Investors should monitor the timely execution of the Bhilwara and Khalapur expansion projects as key margin drivers.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
Stallion India Partners with SYS ADVANCE for Helium Systems; Targets 30-35% Revenue CAGR
Stallion India Fluorochemicals has entered a strategic technology tie-up with Portugal-based SYS ADVANCE to develop Helium Recovery and Liquefaction systems. This partnership provides Stallion with access to technology qualified by European Space Agencies, targeting high-barrier sectors like space and defense. The company is currently participating in a large ISRO tender, which could establish it as a premier technology provider in this niche segment. Management has reiterated a strong 3-year revenue CAGR guidance of 30-35% following this expansion.
முக்கிய அம்சங்கள்
Strategic MoU with SYS ADVANCE for European Space Agency-qualified Helium recovery technology.Management maintains a 3-year revenue CAGR guidance of 30-35% driven by advanced gas technologies.Company has participated in a large tender floated by ISRO for Helium Recovery and Liquefaction.SYS ADVANCE brings global expertise with over 4,000 PSA systems operating in 40+ countries.Expansion supports Stallion's positioning in high-purity industrial and semiconductor gases.
👀 கவனிக்க வேண்டியவை
Investors should monitor the outcome of the ISRO tender as a successful bid would be a major valuation catalyst. The aggressive 30-35% CAGR guidance suggests significant growth potential in the specialized industrial gas market.
Stallion India Fluorochemicals Files DLOF for ₹364 Crore Rights Issue
Stallion India Fluorochemicals Limited has submitted its Draft Letter of Offer (DLOF) for a proposed Rights Issue to raise up to ₹364.00 crores. The issue will involve the offering of fully paid-up equity shares with a face value of ₹10 each to existing eligible shareholders. This capital raising initiative follows the company's recent listing on the main board of BSE and NSE in January 2025. Specific details regarding the issue price, entitlement ratio, and record date are currently pending and will be finalized in the Letter of Offer.
முக்கிய அம்சங்கள்
Proposed Rights Issue size of up to ₹364.00 crores for existing shareholders.Draft Letter of Offer (DLOF) submitted to BSE and NSE on January 24, 2026.Equity shares carry a face value of ₹10.00 each; issue price and ratio to be determined.The company was recently listed on the main board segments on January 23, 2025.Bigshare Services Private Limited has been appointed as the Registrar to the Issue.
👀 கவனிக்க வேண்டியவை
Investors should wait for the announcement of the Rights Issue price and entitlement ratio to evaluate the potential dilution and valuation. Existing shareholders should monitor for the record date to determine eligibility for participation or renunciation of rights.
Stallion India Fluorochemicals to Raise Up to Rs 364 Crore via Rights Issue
Stallion India Fluorochemicals Limited has approved a significant fundraise of up to Rs 364 crore through a rights issue of equity shares. The board has formed a Rights Issue Committee to finalize critical details including the issue price, entitlement ratio, and the record date. Currently, the company has 7,93,25,254 outstanding equity shares. This capital infusion is expected to support the company's financial structure or growth initiatives, though specific utilization details will be provided in the Letter of Offer.
முக்கிய அம்சங்கள்
Board approved a Rights Issue aggregating up to Rs 364.00 Crores.Current outstanding equity shares stand at 7,93,25,254 shares with a face value of Rs 10 each.A Rights Issue Committee has been formed to determine the final price, ratio, and timing.The full issue price will be payable by eligible shareholders at the time of application.
👀 கவனிக்க வேண்டியவை
Investors should monitor for the announcement of the record date and issue price to evaluate the discount and potential dilution of their holdings.
Stallion India Allotted 28,650 Sqm Land for R-32 Plant; Targets ₹500 Cr Revenue
Stallion India Fluorochemicals has secured a 28,650 sq. meter industrial plot from RIICO in Rajasthan to support its R-32 manufacturing facility. The plant, which recently received environmental clearance, will have a 10,000 MTPA capacity for R-32 and 7,500 MTPA for blended refrigerants. Management expects the facility to generate ₹500 crore in annual revenue with PAT margins of 22-24% once commissioned in August 2026. This expansion underpins the company's aggressive 3-year revenue CAGR guidance of 30-35%.
முக்கிய அம்சங்கள்
Allotment of 28,650 sq. meters of land in Rajasthan for R-32 manufacturing expansionPlanned capacity of 10,000 MTPA for R-32 and 7,500 MTPA for blended refrigerantsProjected annual revenue of ₹500 crore with PAT margins between 22-24%Commercial commissioning targeted for August 2026 with construction already startedManagement maintains a 3-year revenue CAGR guidance of 30-35%
👀 கவனிக்க வேண்டியவை
Investors should track the project's execution timeline as the August 2026 commissioning is a key catalyst for revenue growth. The high projected PAT margins suggest significant potential for earnings per share (EPS) accretion.
Stallion India Allotted 28,650 Sq. Mtr. Industrial Plot in Rajasthan for Expansion
Stallion India Fluorochemicals Limited has received an allotment letter from RIICO for an industrial plot in Ukhaliya, Rajasthan. The plot, measuring approximately 28,650 square meters, was secured under the Direct Allotment Policy-2025. This land acquisition is strategically intended to support the expansion and operational requirements of the company's existing R-32 Manufacturing Plant. This move signals a clear commitment to long-term growth and capacity building in the fluorochemicals sector.
முக்கிய அம்சங்கள்
Allotment of Plot No. SP3-11 measuring approximately 28,650 square meters in Ukhaliya, Rajasthan.Plot allotted by RIICO under the 'Direct Allotment Policy-2025' for industrial use.Expansion is designed to support the existing R-32 Manufacturing Plant located at the adjacent Plot No. SP3-10.Strategic acquisition aimed at scaling production capacity and enhancing operational efficiency.
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive growth indicator; monitor future announcements regarding the capital expenditure (CAPEX) and commissioning timeline for the new facility.
Stallion India Receives EC for 10,000 MT R-32 Manufacturing Plant in Rajasthan
Stallion India Fluorochemicals has received a critical Environmental Clearance (EC) from SEIAA, Rajasthan, for its new manufacturing facility in Bhilwara. The approval covers a capacity of 10,000 MT per annum for Difluoromethane (R-32) and 46,460 MT per annum for Hydrochloric Acid as a by-product. Furthermore, the company is authorized to produce 7,500 MT per annum of various blended refrigerants. This clearance is a vital regulatory milestone that paves the way for significant capacity expansion and future revenue growth.
முக்கிய அம்சங்கள்
Received Environmental Clearance for a 10,000 MT per annum R-32 manufacturing plant in Bhilwara, RajasthanAuthorized to produce 46,460 MT per annum of Hydrochloric Acid (30%) as a by-productApproved aggregate capacity of 7,500 MT per annum for blended refrigerants including R-410A and R-407CThe EC is valid for a maximum of ten years, providing long-term regulatory certainty for the project
👀 கவனிக்க வேண்டியவை
Investors should view this as a major de-risking event for the company's expansion plans and monitor the project's construction and commissioning timelines. This capacity addition is expected to be a key driver for the company's top-line growth in the coming years.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
